Portal de Periódicos da CAPES

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors

2005; Taylor & Francis; Volume: 1; Issue: 3 Linguagem: Inglês

10.1517/17425255.1.3.473

1744-7607

Qing Ma, Ólanrewaju O. Okusanya, Patrick F. Smith, Robert DiCenzo, Judianne Slish, Linda M. Catanzaro, Alan Forrest, Gene D. Morse,

Pneumocystis jirovecii pneumonia detection and treatment

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a diverse group of compounds that inhibit HIV Type 1 reverse transcriptase. Although possessing a common mechanism of action, the approved NNRTIs, delavirdine, efavirenz and nevirapine, differ in structural and pharmacokinetic characteristics. Each of the NNRTIs undergoes biotransformation by the cytochrome P450 (CYP) enzyme system, thus making them prone to clinically significant drug interactions when combined with other antiretrovirals. In addition, they interact with other concurrent medications and complementary/alternative medicines, acting as either inducers or inhibitors of drug-metabolising CYP enzymes. These drug interactions become an important consideration in the clinical use of these agents when designing combination regimens, as recommended by current guidelines. This review provides an updated summary of pharmacokinetic interactions with NNRTIs.